Boston Scientific Stent System Gets Big Response
Boston Scientific has completed the initial launch of its TAXUSLiberte paclitaxel-eluting coronary stent system.
Part of the
network
network
Tag: Boston Scientific
Boston Scientific’s $1.6 Billion Increase
Boston Scientific President and CEO, Jim Tobin announced the company's preliminary, unaudited fourth quarter sales results.
